A Crossover Study in the Treatment of Patients With COPD

• Status: Completed
• Trial end date: 2007-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the efficacy of Formoterol Fumarate Inhalation Solution (FFIS) 20 mcg BID to Combivent® Inhalation Aerosol [2 inhalations from metered dose inhaler (MDI)of 18 mcg ipratropium bromide and 103 mcg albuterol sulfate QID], and to Compare the preference/compliance of BID nebulization to QID use of MDI

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dey
• Treatments: Albuterol; Bromides; Formoterol Fumarate; Ipratropium

Criteria

Inclusion Criteria:

• Diagnosis of COPD

• Smoker or exsmoker with at least 10 years smoking at least one pack of cigarettes per day

• Meet lung function requirements

Exclusion Criteria:

• Diagnosis of Asthma

• Significant disease other than COPD

• Female pregnant or lactating or planning to become pregnant